Kistler-Tiffany Companies’s Viking Therapeutics VKTX Stock Holding History

Kistler-Tiffany Companies’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$24.3K	Sell	1,500 -450	-23%	-$9.43K	﹤0.01%	594
2023 Q1	$32.5K	Buy	1,950 +450	+30%	+$4.65K	0.01%	480
2022 Q4	$14.1K	Hold	1,500	–	–	﹤0.01%	585
2022 Q3	$4K	Hold	1,500	–	–	﹤0.01%	696
2022 Q2	$4K	Hold	1,500	–	–	﹤0.01%	683
2022 Q1	$5K	Hold	1,500	–	–	﹤0.01%	669
2021 Q4	$7K	Hold	1,500	–	–	﹤0.01%	631
2021 Q3	$9K	Hold	1,500	–	–	﹤0.01%	604
2021 Q2	$9K	Hold	1,500	–	–	﹤0.01%	583
2021 Q1	$9K	Hold	1,500	–	–	﹤0.01%	536
2020 Q4	$8K	Hold	1,500	–	–	﹤0.01%	522
2020 Q3	$9K	Hold	1,500	–	–	﹤0.01%	494
2020 Q2	$11K	Hold	1,500	–	–	﹤0.01%	439
2020 Q1	$12K	Hold	1,500	–	–	﹤0.01%	421
2019 Q4	$12K	Hold	1,500	–	–	﹤0.01%	427
2019 Q3	$10K	Hold	1,500	–	–	﹤0.01%	452
2019 Q2	$12K	Hold	1,500	–	–	﹤0.01%	425
2019 Q1	$15K	Hold	1,500	–	–	0.01%	384
2018 Q4	$11K	Buy	+1,500	New	+$17.9K	0.01%	395

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Kistler-Tiffany Companies's VKTX Position: Q2 2023 in Review

Kistler-Tiffany Companies reduced its Viking Therapeutics (VKTX) stake by 23% in Q2 2023, selling an estimated $9.43K and leaving 1,500 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #594.

Kistler-Tiffany Companies first reported a position in VKTX in Q4 2018 and has held it in 19 quarters since. The position peaked at $32.5K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

Kistler-Tiffany Companies held 1,500 shares of Viking Therapeutics worth $24.3K as of Q2 2023.
Kistler-Tiffany Companies sold 450 Viking Therapeutics shares in Q2 2023, an estimated $9.43K.
Viking Therapeutics made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #594 holding.
Kistler-Tiffany Companies first reported a position in Viking Therapeutics in Q4 2018 and has held it in 19 quarters since.
Kistler-Tiffany Companies's Viking Therapeutics position peaked at $32.5K in Q1 2023.
193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.